FVD regimen demonstrated a 7.8 month difference in median PFS vs placebo/bortezomib (BTZ)/dexamethasone (dex) (12.5 vs 4.7 months) in patients who received at least 2 prior regimens, including BTZ and an immunomodulatory drug (IMiD).1
For Health Care Professionals Outside the US
FVD regimen demonstrated a 7.8 month difference in median PFS vs placebo/bortezomib (BTZ)/dexamethasone (dex) (12.5 vs 4.7 months) in patients who received at least 2 prior regimens, including BTZ and an immunomodulatory drug (IMiD).1
Reference: